Analyst Price Targets — GERN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 27, 2025 10:13 am | Peter Lawson | Barclays | $4.00 | $1.61 | TheFly | Geron price target lowered to $4 from $9 at Barclays |
| November 5, 2024 11:02 am | Emily Bodnar | H.C. Wainwright | $8.00 | $4.24 | StreetInsider | H.C. Wainwright Starts Geron Corporation (GERN) at Buy |
| October 22, 2024 6:52 am | Kalpit Patel | B.Riley Financial | $5.50 | $3.95 | StreetInsider | B.Riley Reiterates Buy Rating on Geron Corporation (GERN) ahead of Q3 |
| September 9, 2024 6:23 am | Faisal Khurshid | Leerink Partners | $7.00 | $4.25 | TheFly | Geron initiated with an Outperform at Leerink |
| June 10, 2024 11:59 am | Corinne Jenkins | Goldman Sachs | $6.00 | $4.95 | StreetInsider | Geron Corporation (GERN) PT Raised to $6 at Goldman Sachs |
| June 10, 2024 6:39 am | Stephen Willey | Stifel Nicolaus | $7.00 | $4.59 | TheFly | Geron price target raised to $7 from $6 at Stifel |
| April 30, 2024 2:33 am | Joel Beatty | Robert W. Baird | $4.50 | $4.14 | StreetInsider | Baird Downgrades Geron Corporation (GERN) to Neutral 'on Valuation Concerns' |
| March 15, 2024 7:12 am | Gil Blum | Needham | $5.00 | $3.36 | StreetInsider | Geron Corporation (GERN) PT Raised to $5 at Needham, 'anticipate imetelstat will receive the go-ahead on or prior to its June 16 PDUFA date' |
| March 15, 2024 3:51 am | Corinne Jenkins | Goldman Sachs | $5.00 | $3.36 | StreetInsider | Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs |
| January 9, 2023 10:30 am | — | Needham | $4.00 | $2.79 | Benzinga | Needham Maintains Buy on Geron, Raises Price Target to $4 |
Latest News for GERN
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media…
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron (NASDAQ: GERN) executives used a presentation at the Needham Healthcare Conference to outline the company's early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamics, and discuss the ongoing Phase 3 myelofibrosis (MF) program. Commercial launch status and financial outlook…
FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron's new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of…
Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GERN.
U.S. House Trading
No House trades found for GERN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.